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Abstract
This paper focused on formulating high-performance curcumin spray-dried powders for inhalation (curcumin-DPIs)
to achieve a high lung concentration. Curcumin-DPIs were produced using wet milling combined with the spray
drying method. The effects of different milling times on particle size and aerodynamic performance were
investigated. The curcumin-DPIs were characterized by scanning electron microscopy (SEM), differential scanning
calorimetry (DSC), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR), and in vitro
dissolution. Furthermore, the in vivo pharmacokinetic behavior and tissue distribution after pulmonary
administration were also evaluated. Results showed that the drug dissolution was significantly enhanced by
processing into curcumin-DPIs. The aerodynamic results indicated that the DPIs displayed a good aerosol
performance. The plasma curcumin concentration was obviously enhanced by inhalation, and most of the
curcumin-DPIs were deposited in the lung. This study demonstrated that inhalation was an effective way to carry
drug to the lung, and curcumin-DPIs were hopeful for lung cancer treatment in the future.
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Background
Curcumin is a yellow substance isolated from the rhizome
of Curcuma longa [1], which has extensive pharmaco-
logical actions such as antitumor [2], anti-inflammatory
[3], and antioxidant effects [4]. Curcumin is pharmaco-
logically safe and is used as a dietary spice and food addi-
tive. Some researchers reported that curcumin can
effectively inhibit tumor cell proliferation, migration, and
invasion [5]. However, the clinical application of curcumin
is limited due to its extremely low aqueous solubility, in-
stability in aqueous solution, rapid metabolism, and poor
bioavailability [6].
In order to solve this problem, reducing the particle
sizes to nanoscale by wet milling is often used. Wet mill-
ing is considered to be one of the best approaches to
prepare nanocrystals for large-scale production [7]. The
mixed coarse suspension of drug and stabilizers are fed
into the grinding jar with grinding media. The mechan-
ical attrition is a high-energy process with high-speed
shear force and impact force, which can produce suspen-
sions with smaller size. As an efficient and convenient
method, wet milling technique can sharply increase the
surface area of drug particles and improve the dissol-
ution rate [8], resulting in a better absorption [9].
In recent years, pulmonary drug delivery brings great
interest to researchers due to many advantages in both
local and systemic treatments over other delivery routes.
The lung has relatively large surface areas (43 to 102 m2),
thin absorption barriers, and low proteolytic activities.
The lung has significant blood capillaries to make the drug
be absorbed rapidly, and the pulmonary administration
could avoid first-pass effect of the liver [10].
The technology of dry powders for inhalation (DPI) is
propellant-free, portable, and easy to operate, and it has
better stability for inhalation. DPI can target drug to the
lung and result in an effective therapeutic concentration
at the pathological site. DPI also provides a sustained ef-
fect with a minimal administration dosage, and reduces
the frequency of medication and increases the patients’
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compliance. DPI requires drug particles with optimum
size and good flow property to ensure accurate dose for
better inhalation. Spray drying is an ideal technique be-
cause it can produce spherical particles with good uni-
formity and mobility.
In this study, wet milling technique in combination with
spray drying was used to prepare curcumin-DPIs and the
milling time was optimized. Physicochemical properties of
the powders were characterized by differential scanning cal-
orimetry (DSC), powder X-ray diffraction (PXRD), Fourier
transform infrared spectroscopy (FTIR), scanning electron
microscopy (SEM), and in vitro dissolution. The plasma
curcumin concentration and in vivo tissue distribution were
also investigated. Results showed that inhalation was an ef-
fective way to carry drug to the lung, and curcumin-DPIs
were hopeful for lung cancer treatment in the future.
Methods
Materials
Curcumin was obtained from Sinopharm Chemical Re-
agent Co., Ltd. (Shanghai, China). Tween 80 was purchased
from Yibei Chemical Reagent (Tianjin, China). Methanol
and ethanol were both provided by Beichen Founder Re-
agent Plant (Tianjin, China). Acetonitrile was obtained
from Kermel Chemical Reagent Co., Ltd. (Tianjin, China).
Sodium dodecyl sulphate was purchased from Tianjin
Baodi Chemical Holding Co., Ltd. (Tianjin, China). Acetic
acid glacial was purchased from Fuchen Chemical Reagent
(Tianjin, China). All other chemicals were of analytical
grade. Distilled water was used throughout the study.
Preparation of Curcumin Nanocrystals
The nanocrystals were prepared using a MiniZeta
(NETZSCH Machinery and Instruments Co., Ltd.,
Germany) machine. The grinding media was yttrium-
stabilized zirconium oxide bead (0.6 mm in diameter).
Before milling, 20 g curcumin was dispersed in 250 mL
aqueous solution of 6.25 % Tween 80 (relative to the
drug amount) under magnetic stirring, until a rela-
tively uniform coarse suspension was obtained. Then,
the coarse suspension was transferred to the milling
bowl. The system temperature was maintained at less
than 25 °C by passing cooling water through the outer
jacket continuously.
Spray Drying of Curcumin Nanocrystals
The nanocrystals were spray-dried with an YC-015 ex-
perimental spray drier (Shanghai, China). The operating
condition was set as follows: inlet temperature of 170 °C,
outlet temperature of 90 °C, and liquid feed rate of
3 mL/min. A magnetic stirrer was used to keep the sus-
pension homogenized. Dried powders were collected in




The particle sizes of samples before and after wet milling
were evaluated by the laser diffraction method using a
BT-9300S laser particle size analyzer (Dandong, China).
Each sample was diluted with purified water to achieve a
suitable concentration for measurement. Results were
expressed as D50, D90 and D97, which meant 50, 90, and
97 % of the particles were smaller than the rest of the
distribution, respectively.
Drug Loading
To quantify the curcumin content, a certain amount of
curcumin-DPIs was dissolved in ethanol and mixed by
ultrasonication for 10 min. The solution was diluted to
a suitable concentration with ethanol and filtered
through a 0.45-μm filter membrane. The subsequent
filtrate was assayed by high-performance liquid chro-
matography (HPLC) to determine the concentration of
curcumin. The HPLC system consisted of two LC-20A
pumps and an SPD-20A UV/VIS detector (Shimadzu,
Kyoto, Japan). The column used was Thermo C18
(250 × 4.6 mm). Acetonitrile/water (containing 0.05 %
acetic acid glacial) (60:40, mL/mL) was used as the mo-
bile phase with a flow rate of 1 mL/min. The wave-
length was set at 428 nm.
Aerodynamic Particle Size
The aerodynamic particle size was evaluated using a
next generation impactor (model 170 NGI, MSP Cor-
poration), which was equipped with a pre-separator
[12]. The flow rate was adjusted to 60 L/min. The dry
powder inhaler was fitted with a size 3 HPMC capsule.
Deposited drugs in the device, throat, and cups were
removed with ethanol and collected in volumetric
flasks. The cutoff diameters of stages 1, 2, 3, 4, 5, 6,
and 7 were 8.06, 4.46, 2.82, 1.66, 0.94, 0.55, and
0.34 μm, respectively. Stage 8 referred to capturing the
remaining fractions of particles less than 0.34 μm. Each
stage of the impactor was coated with silicone prior to
analysis in order to minimize particle bounce. Drug de-
position was determined by a validated HPLC method
described above. Fine particle fraction (FPF) was used
to describe the quality of an inhalation formulation.
FPF was calculated as the fraction of a formulation that
is in a size range with the potential to penetrate and
deposit in the airways. The following formula was used
to calculate FPFloaded and FPFemitted:
FPFloaded ¼ powder amount on stages 2−8total amount recovered ð1Þ
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FPFemitted
¼ powder amounton stages 2−8
total amount recovered−capsule and device retention
ð2Þ
DSC, FTIR, and PXRD
DSC was conducted using a DSC822E differential scan-
ning calorimeter (PerkinElmer, USA) to examine the ther-
mal properties of different formulations. The samples
were accurately weighed and placed in a crucible with an
empty crucible as the reference. The temperature ranged
from 32 to 250 °C with a heating rate of 10 °C/min.
FTIR spectra were tested using a FTIR spectrometer
(Shimadzu 8400S, Japan). Each sample was mixed with
potassium bromide of IR grade and compressed using
an IR pellet manufacturing machine.
PXRD was imaged by a Y2000 powder X-ray diffract-
ometer (Dandong, China). The powders were placed in
the sample slot and pressed smoothly with frosted glass.
Then, samples were put into an instrument with a scan
speed at 0.04°/min, and the patterns were recorded over
2θ, with the angle ranged from 5° to 50°.
In Vitro Dissolution
The dissolution behaviors of bulk curcumin and
curcumin-DPIs were investigated by the paddle method
using a ZRS-8G dissolution apparatus (Tianjin, China) at
a rotation speed of 100 rpm in 900 mL 0.3, 0.5, and 1.0 %
sodium dodecyl sulfate (SDS) aqueous solution (g/mL), re-
spectively. The temperature was maintained at 37 ± 0.5 °C.
At specific time intervals, 5 mL of samples was withdrawn
and immediately replaced with the same amount of fresh
media. All the samples were passed through a 0.45-μm fil-
ter membrane and then examined with an UV spectro-
photometer at 428 nm.
Scanning Electron Microscopy
Surface morphologies of bulk curcumin and curcumin-
DPIs were investigated by SEM (JSM-7500 F, Japan).
Samples were fixed on stubs using a double-sided tape
and coated with gold under a high-vacuum atmosphere
and then observed at an acceleration voltage of 10 kV.
Stability
Curcumin-DPIs were sealed in small bottles and stored
at 4 and 25 °C, respectively. The concentration was mea-
sured after 60 days. Any decrease in the drug content or
occurrence of extra drug impurity in chromatograms
would be considered as instability.
Pharmacokinetic Study and Tissue Distribution
In this study, 12 rabbits were housed in separate cages
and received food and water ad libitum. Twelve hours
before experiments, the rabbits were randomly sepa-
rated into two groups and fasted but with free access to
water. Rabbits were anesthetized with chloral hydrate
(100 mg/kg, i.v.) and received endotracheal insufflation
Fig. 1 Particle sizes of unmilled bulk curcumin (0 min) and nanocrystals milled with different times
Hu et al. Nanoscale Research Letters  (2015) 10:381 Page 3 of 9
and oral administration of curcumin-DPIs (25 mg/kg),
respectively. Blood samples were taken from the ear
vein at predetermined intervals (0, 0.5, 0.75, 1, 2, 3, 4, 6,
and 8 h) and collected in heparinized tubes. Total blood
was centrifuged at 10,000 rpm for 10 min, and 200 μL
of plasma was collected and stored at −20 °C until
analysis.
Tissue distribution was studied on Wistar rats (250 ±
20 g). Before the experiments, they were randomly sepa-
rated into two groups and anesthetized with urethane
(1 g/kg, i.p.) and then received pulmonary administration
of curcumin-DPIs (25 mg/kg). At determined time points
(0.5, 2, 4, and 6 h), the rats were sacrificed, and the tissues
including the heart, liver, spleen, lung, kidney, and brain
were collected, weighted, and frozen at −20 °C until fur-
ther analysis.
For plasma samples, 0.6 mL ethanol was added into
0.2 mL plasma, vortexing for 5 min. Then, the mixture
was centrifuged to obtain the supernatant. For tissue
samples, the tissues were formulated into homogenates
using saline solution. 0.5 mL of tissue homogenates were
collected and 1 mL methanol was added. The mixture
was vortexed for 3 min and centrifuged at 10,000 rpm
for 10 min, then the supernatant was collected. Concen-
trations of curcumin in plasma and tissue samples were
measured by a HPLC method mentioned above.
Results and Discussion
Effects of Milling Time
The effects of milling time on particle sizes were shown
in Fig. 1. For all cases, the concentration of Tween 80
was kept 6.25 % relative to the drug amount and the agi-
tator speed was 3000 rpm. Before milling, the D50, D90,
and D97 of bulk curcumin were 15.08, 47.19, and
75.01 μm, respectively.
It was found that the particle sizes decreased obviously
with increasing milling time. After milling for 10 min,
the D50 of curcumin dramatically decreased to less than
1.5 μm. Nanocrystals with smaller and more uniform
particle size were obtained by prolonging milling time.
The D50 decreased to 1277 nm after milling for 10 min,
1268 nm for 20 min, 1086 nm for 30 min, and 924 nm
for 40 min. It could be concluded that extending the
milling time would provide more energy to break the
crystals into smaller ones and give sufficient spreading
time for Tween 80 to attach onto the particle surfaces.
In addition, further increasing the milling time to
60 min did not remarkably decrease particle size
(Additional file 1).
Fig. 2 Next generation impactor deposition profiles of curcumin-DPIs milled with different times
Table 1 Aerodynamic properties of curcumin-DPIs dispersed at
60 L/min with different milling times
Time (min) FPFloaded (%) FPFemitted (%) Capsule and device retention (%)
10 59.9 62.4 3.8
20 64.9 67.9 4.1
30 68.9 72.1 4.3
40 68.8 72.3 4.5
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Aerodynamic Particle Size
The deposition site in the respiratory tract and the in-
haled efficiency were critically influenced by particle size
distributions. Figure 2 showed the aerosol behavior of
the spray-dried powders with different milling times.
The FPFloaded and FPFemitted were 59.9 and 62.4 % for
10 min, 64.9 and 67.9 % for 20 min, 68.9 and 72.1 % for
30 min, and 68.8 and 72.3 % for 40 min, respectively
(Table 1). The differences in the deposition patterns may
be due to the decrease in the particle sizes. Furthermore,
it was reported that inhaled particles below 5 μm could
be able to penetrate into the lung [13]. So, most of the
spray-dried powders could penetrate into the lung, thus
increasing the curcumin’s lung deposition. In spite of the
higher powder dispersion behavior, the dried powders
still had a small amount of capsule and device retention.
Fig. 3 DSC curves of bulk curcumin and curcumin-DPIs milled with different times
Fig. 4 PXRD patterns of bulk curcumin and curcumin-DPIs milled with different times
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Powders may adhere in the capsule and the inhalation
device during the emission process. Results showed that
the powders milling for 30 and 40 min had higher
FPFloaded and FPFemitted values and the former had a
smaller capsule and device retention. So the milling time
was set as 30 min for curcumin-DPI production, which
could ensure a good aerosol performance.
Characterizations
Thermal Analysis
In Fig. 3, the bulk curcumin exhibited a sharp endotherm
peak with melting point at 186.2 °C, while the melting
point of curcumin-DPIs was between 183.2 and 183.7 °C.
The melting point of curcumin-DPIs shifted forward with
significant reduction in peak intensity, and it may be
Fig. 5 FTIR spectra of bulk curcumin and curcumin-DPIs milled with different times
Fig. 6 Dissolution profiles of curcumin-DPIs and bulk curcumin in different media
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caused by the interactions between curcumin and the co-
grinding surfactant in the experimental process.
PXRD Analysis
As seen from the PXRD results in Fig. 4, there were
some differences of the polymorphic forms between bulk
curcumin and curcumin-DPIs. The bulk curcumin main-
tained the crystalline state well, while curcumin-DPIs
had the lower peak intensities, suggesting the lower crys-
tallinity and the smaller sizes, which was consistent with
the SEM results.
FTIR Analysis
The chemical compositions of bulk curcumin and
curcumin-DPIs were evaluated by FTIR spectra, and it
could be seen that there were no obvious differences be-
tween the two samples in the whole area of curcumin ab-
sorption bands. As shown in Fig. 5, the FTIR analysis
showed absorption at 1720 cm−1 for C=O stretching of
the ester group, at 1650 cm−1 for C=O of the ketone
group, at 1300 cm−1 for the ether group, and at 2980 cm−1
for aromatic stretching. A sharp band at about 3500 cm−1
and the broad peak at 3200–3500 cm−1 in the spectrum
have been attributed to the –OH group stretching vibra-
tion. It could be concluded that milling and spray drying
did not change the chemical compositions of curcumin.
Dissolution Test
Figure 6 showed the dissolution behavior of bulk curcu-
min and curcumin-DPIs. Curcumin-DPIs showed a higher
dissolution of about 98 % at 4 h with 1 % SDS, 87 % with
0.5 % SDS, and 74 % with 0.3 % SDS, while the dissolution
from bulk curcumin was about 90 % with 1 % SDS, 81 %
with 0.5 % SDS, and 62 % with 0.3 % SDS. The dramatic
increase of dissolution could be attributed to the following
reason. According to the Noyes-Whitney equation, the
curcumin-DPIs had a smaller size and a larger surface area
with a higher apparent saturation solubility, which pro-
nouncedly enhanced the dissolution rate. In addition, the
dissolution rate could be improved significantly with the
SDS concentration increasing.
SEM Analysis
The SEM results (Fig. 7) presented that the bulk curcu-
min was in a tabular shape and had a broad particle size
distribution. In contrast, the curcumin-DPIs showed
spherical, uniform small particle sizes. It was found that
some fine crystals adhered with each other during spray-
ing by electrostatic and van der Waals forces, and the
particle size became larger. During spray drying, the
nanocrystals were sprayed in the form of a lot of small
droplets and each droplet consisted of many fine parti-
cles. These particles aggregated together after water
evaporated instantly, and the aggregates were hard to
break into individual particles.
Drug Loading and Stability Analysis
The drug loading of curcumin-DPIs was measured.
There were no obvious changes of curcumin-DPIs after
storage for 60 days. No significant differences about par-
ticle size and flowability were found, and the curcumin
content remained constant and no degradation peaks
were found in HPLC chromatography. Therefore, the
curcumin-DPIs showed good physical and chemical
stability.
Pharmacokinetic and Biodistribution Study
The concentration-time profiles after pulmonary and
oral administration are shown in Fig. 8, and pharmacoki-
netic parameters are summarized in Table 2.
The curcumin concentration decrease from the plasma
appeared for the pulmonary administration to be in two
distinct phases with an initial rapid elimination occur-
ring in the first hour followed by a slower elimination
Fig. 7 a SEM images of bulk curcumin. b SEM images of curcumin-DPIs
Hu et al. Nanoscale Research Letters  (2015) 10:381 Page 7 of 9
from 1 to 8 h. The first phase probably corresponded to
the rapid absorption and distribution of the drug into
the systemic compartment until equilibrium was reached
between the systemic circulation, the lung, and the dif-
ferent tissues, after which the elimination phase took
place. Significant differences were found between the
two administration routes. The plasma curcumin con-
centration was much higher for pulmonary administra-
tion than for oral administration.
The average peak concentration (Cmax) of the inhalation
group (27.52 mg/L) was higher than that of the oral group
(3.64 mg/L), and Tmax of the inhalation group was ad-
vanced compared with that of the oral group (0.5 versus
3 h), which indicated a greater and faster absorption after
pulmonary administration. The shorter Tmax observed for
the pulmonary group may also be explained by the higher
solubility of curcumin-DPIs. The higher solubility was
probably correlated with faster in vivo dissolution velocity,
as described by the Noyes-Whitney equation, accelerating
absorption onset from the lung. AUC0–∞(area under the
curve) of the pulmonary group was 37.24mg L−1 h−1,
which was about 3.2-fold higher than that of the oral
administration group (11.75 mg L−1 h−1). MRT (mean
retention time) of the oral group was 3.05 h, while MRT
of the pulmonary group was 2.65 h. Results showed that
the curcumin-DPIs could increase the curcumin absorp-
tion rate and amount. The bioavailability of curcumin was
significantly enhanced by the inhalation delivery.
Figure 9 showed the tissue curcumin concentrations of
curcumin-DPIs. After pulmonary administration, the distri-
bution of curcumin in the lung was dramatically increased
at the predetermined time points compared with other tis-
sues. Six hours after pulmonary administration, curcumin
concentration in the lung was still high (824.27 μg/g), while
a relatively low distribution in the liver (3.06 μg/g), kidney
(6.10 μg/g), heart (4.23 μg/g), spleen (13.77 μg/g), and brain
(0.53 μg/g) was found at the same time. The biodistribu-
tion study in rats indicated that curcumin-DPIs would
mostly be deposited in the lung, which could enhance the
lung curcumin concentration and decrease curcumin con-
centration in other tissues, thus reducing the systemic tox-
icity and improving the therapeutic effects.
Conclusions
In this study, curcumin-DPIs were successfully prepared
using wet milling technique followed by spray drying.
DSC, PXRD, and FTIR tests showed that the crystalline
state of curcumin was not changed during the particle
size reduction. The aerodynamic performance showed
that the milling time of 30 min was most suitable for
inhalable administration. The products could be stored
for 60 days, and no degradation was found. The pharma-
cokinetic study demonstrated that curcumin-DPIs could
enhance bioavailability of curcumin with a higher AUC
and Cmax than those of oral administration. The in vivo
Table 2 Mean pharmacokinetic parameters of rabbits after
pulmonary and oral administration
Parameters Pulmonary administration Oral administration
T1/2 (h) 1.46 2.15
Cmax (mg/L) 27.52 3.64
AUC (mg L−1 h−1) 37.24 11.75
MRT (h) 2.65 3.05
Fig. 8 Mean plasma concentration profiles of curcumin-DPIs in rabbits after pulmonary and oral administration
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tissue distribution showed that most of the curcumin-
DPIs were deposited in the lung, thus reducing the con-
centrations in other tissues. Results showed that DPI
was a potential drug delivery system for the effective
treatment of the lung diseases with improved lung con-
centration and reduced systematic toxicity.
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